Articles On Althea Group Holdings (ASX:AGH)

Imugene takes the road to China with a new cell-therapy collab Heramed strikes its second US deal within two days Beverage play Althea says things go better with THC   From China to Canada to the US, ASX life science plays are striking o...

ASX recovers from 0.7pc plunge to lose just 0.13pc Gains in energy offset larger losses in gold and healthcare IEL and GYG power consumer discretionary higher ASX makes staged recovery Things weren’t looking great on the ASX 200 this mor...

4D Medical shares gain up to 40% on FDA lung imaging device approval Lumos wins US funding for kids’ flu-versus-virus trial ‘Spend money to make money’: the lesson from the last-minute reporters   In an “historic moment in respiratory dia...

The recently completed sale of Althea Group's (ASX: AGH) medicinal cannabis business finalised its pivot to selling THC drinks in North America, and with it the tenure of founder and CEO Josh Fegan. The former Strathfield Car Radio franchi...

• Several emerging life science plays are taking revenue to new heights – and some have even turned profitable • Little Green Pharma seeks to avoid a second pay ‘strike’ • Althea founder exits the building   It is a truth, universally ackn...

Cannabis suppliers are struggling to differentiate themselves in a commoditised market Regulators have lax telehealth prescribers in their sights Althea Group has sold its medical pot arm in favour of THC-infused beverages     Having spro...

We just added Althea Group Holdings (ASX: AGH) to our Portfolio.  AGH is targeting one of the fastest growing consumer industries in the USA… THC-infused drinks as a replacement for alcohol.

Medadvisor shares soar up to 60% after the company flags the sale of its Australian business Pot stock Althea sees better fortunes in the THC-infused beverage sector Clinuvel’s phase III vitiligo trial is fully recruited   With operation...

Highlights: CEO Joshua Fegan made a significant stock purchase in Althea Group Holdings (ASX:AGH). Over the last year, the company experienced a net buying trend in insider transactions. Despite strong insider alignment, the...

Highlights: Althea Group Holdings exhibits a low price-to-sales ratio, reflecting its below-industry valuation. The company has shown positive revenue growth, though it trails behind industry growth projections. Investor sen...

Nanocap Althea Group (ASX:AGH) has locked in $4 million via a placement to expand its North American THC-containing beverage operations, an announcement firm enough to push up shares 10% to 2.2cps through this morning. Listen to the HotC...

Medicinal cannabis company Althea Group (ASX: AGH) has withdrawn from a potential vape contract worth almost the same as a whole quarter of its revenue, citing regulatory, ethical, financial, and strategic concerns with the category. In it...

Althea Group Holdings Ltd (ASX:AGH) has sold its MyAccess Clinics business in the United Kingdom and Ireland to Montu UK Ltd for $1 million as part of a streamlining plan. MyAccess, which manufactures and retails cannabis products, provi...

Althea Group (ASX: AGH) has ramped up its cost cutting drive with an agreement to sell its MyAccess Clinics business in the UK and Ireland to a subsidiary of fellow Melbourne-based medicinal cannabis group Montu for $1 million. Althea laun...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX and regional markets are sharply lower after Wall St tech crunch All 11 local sectors hit, InfoTech smashed hardest on -2.7pc Tissue Repair leads small caps on happy TGA approval news   The benchmark has followed sharp falls across...

Althea’s US subsidiary enters key joint venture to target the legal US cannabis-infused beverages market The market is valued at nearly US$967 million and projected to reach US$19 billion by 2028 Five flavoured beverages have been develop...

Immutep receives FDA feedback for its TACTI-004 Phase III trial design for tackling non small-cell lung cancer Althea forms JV to enter the US cannabis beverage market Chimeric enrols first participant in a Phase 1/2 trial for its CHM CDH1...

Althea Group (ASX:AGH) has inked agreements “to establish [a] joint venture” with Flora Growth Corporation to make cannabis-based beverages. Althea cited figures on Monday claiming the cannabis beverages market is worth just short of USD...

The ASX is set to fall when it opens Monday, following Wall Street’s losses Major tech stocks like Nvidia and CrowdStrike saw drops, while crude oil tumbled 3pc President Biden has ended his re-election bid   The ASX200 index is expected...

The cannabis industry is poised for growth, driven by evolving legalisation globally Investment opportunities therefore exist across the sector We take a look at the ASX weed stock winners over the past month    The cannabis industry is c...

ASX 200 adds about 60 points after intraday record Nine of 11 sectors higher, IT weighed by US megatech losses Pearl Gull Iron pops on REE in Chile   Local markets surged on Friday following positivity overnight on Wall Street after so...

Althea Group launches new medical cannabis dried flowers in Aus and UK GMP-certified range developed with Rocket Factory Company plans to launch more products in the future   Special Report: Althea Group has launched its new medicinal ca...

  Althea navigates shifts in cannabis market by restructuring its operations and aiming for positive EBITDA by FY25 Althea’s subsidiary, Peak, eyes growth in its recreational cannabis business Peak is set to capitalise on the lucrative US...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX drops over 1pc as tech, retail, banks fall; energy resists Bond yields surge, impacting goldies Ethereum ETFs approved, await filings   Energy was the only sector showing some sort of resistance on Friday as the ASX was engulfed in a...

Althea Group Holdings is on a high today, up 11 percent on the ASX on announcing that its Canadian subsidiary, Peak Processing, has joined forces with Flora Growth to introduce cannabis drinks to the US beverages market. The cannabis med...

PYC Therapeutics gets FDA approval PYC Therapeutics (ASX:PYC) has received an Orphan Drug Designation (ODD) from the US FDA for its drug candidate, PYC-001, aimed at treating OPA1-associated vision loss. The ODD is a special designation giv...

ASX 200 set for losses on US market woes and Fed uncertainty Nvidia soars while Boeing falters; Live Nation hit by antitrust worries SpaceX eyes share sale, aiming for $200B valuation   The ASX 200 is poised for sharp losses again when...

So it’s been a dark few years for the brave new world which was cannabis investing. That’s changed suddenly, powerfully with the alignment of two unlikely stars. The first is this:   And the second – even more unlikely, is this:   That’s...

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

Australian-founded medicinal cannabis company Althea Group (ASX: AGH) has announced staff redundancies that have shaved $1.5 million from its cost base as the first phase of a planned restructure in the wake of a challenging time for the se...

Medicines cannabis company Althea Group Holdings (ASX:AGH) has updated on developments in France’s generalisation of the use of related products.

Material uncertainties have been raised about two of the largest medicinal cannabis companies listed on the ASX to continue as going concerns, after Cann Group (ASX: CAN) and Althea Group (ASX: AGH) incurred December half losses of $14.3 mi...

Cannabis stocks could rise after the removal of US House Speaker Montu says TGA has to allow the term ‘medicinal cannabis’ to be used We look at the best performing ASX weed stocks over the past month   Some experts believe cannabis stock...

Althea’s cannabis oil approved for reimbursement in Ireland Imugene dosed first patient in onCARlytics Phase 1 trial on solid tumours   Althea’s cannabis oil approved for reimbursement Cannabis company Althea Group (ASX:AGH) has announced...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Global Health announces deal with Fujitsu Australia Althea raises $5.32m in sale and leaseback deal Immutep to present data from TACTI-002 in key international forum   Global Health signs with Fujitsu Global Health (ASX:GLH), a provider o...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Stockhead’s Top 10 at shortly-before-11-ish, produced as on-time as humanly possible, despite being handicapped by some decidedly non-human and highly-unfriendly technology. On a slightly-related note, if anyone out there needs parts for an...

Althea extends contract in Canada Clarity moves forward to cohort 3 Cynata opens Phase 2 recruitment   Althea extends deal in Canada for cannabis drinks Cannabis company Althea Group (ASX:AGH) announced that its wholly owned subsidiary, P...

ASX cannabis share Althea Group Holdings Ltd (ASX: AGH) leapt by as much as 27% this morning after the company revealed record quarterly sales of $9.24 million. The company also achieved its maiden monthly operating profit in March, and...

Althea Group (AGH) secures an additional $2.2 million in funding through convertible notes The funding boost comes from US-based institutional investor, Obsidian Global Partners The money will support the launch of AGH’s new SKU’s, an...

Two more US states join the 19 that already allow legal recreational cannabis use ECS Botanics’ Victorian medical cannabis facility is safe from flooding in the state, so far Cann looks to commercialise its Satipharm CBD capsules for over-...

Cannabis-based medicine supplier Althea Group (AGH) receives firm commitments to raise $1.5 million via a share placementThe money will be raised through the issue of 22.4 million new fully-paid ordinary shares to institutional and sophisti...

Althea Group (AGH) enters a trading halt while it plans an upcoming capital raiseIn its September quarterly report, the medicinal cannabis company says the capital raise will “improve its financial position” after a period of increased oper...

It’s time to get cozy and laugh at the lunacy that’s been unfolding here – and abroad – at the intersections of business, entertainment and news, and perilously close to the boundaries of good taste. So let’s kick off our sensible polyester...

ASX 200 rises over 1% on Monday after strong US leads, before Tuesday RBA meeting Small cap index finds nuthin’ as energy, materials fall Up circa 550%, WA1 is still rising   This is happening. Always trust a chartered professional accoun...

Cambridge says cannabis smokers are not actually lazy, that’s a myth USyd wants to test home-grown cannabis in the ACT Incannex joins the big leagues S&P/ASX300 index   It turns out that the lazy stoner stereotype is actually a myth,...

Invion’s lead drug is found to be effective against anal cancer Althea launches new cannabis products Invion (ASX:IVX) surged 17% this morning after telling the market that its lead drug INV043 is effective against anal cancer. A vitro st...